Similar articles

• [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].

  Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E. Cartei G, et al. Minerva Med. 1978 Mar 17;69(13):811-21. Minerva Med. 1978. PMID: 643223 Italian. No abstract available.
• [Biologically active hydroxamic acids--iron complexons].

  Kol'tsova GN, Mel'nikovskaia NN, Likhodzievskiĭ KG, Rozenberg GIa. Kol'tsova GN, et al. Gematol Transfuziol. 1984 Sep;29(9):56-9. Gematol Transfuziol. 1984. PMID: 6394425 Review. Russian. No abstract available.
• Iron metabolism and iron chelation in the thalassaemia disorders.

  Pippard MJ. Pippard MJ. Haematologica. 1990 Sep-Oct;75 Suppl 5:66-71. Haematologica. 1990. PMID: 2086383 Review. No abstract available.
• Chronic iron overload: new chelators and new strategies.

  Fairbanks VF. Fairbanks VF. J Lab Clin Med. 1978 Aug;92(2):141-3. J Lab Clin Med. 1978. PMID: 681806 No abstract available.
• Chelation therapy for iron overload.

  [No authors listed] [No authors listed] Nutr Rev. 1980 May;38(5):185-7. doi: 10.1111/j.1753-4887.1980.tb05889.x. Nutr Rev. 1980. PMID: 7207885 No abstract available.